SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmBusiness Wire • 07/16/20
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmBusiness Wire • 07/16/20
VRCA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the FirmNewsfile Corp • 07/15/20
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Verrica Pharmaceuticals Inc.Business Wire • 07/15/20
VERRICA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Verrica Pharmaceuticals, Inc.Business Wire • 07/14/20
The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Verrica Pharmaceuticals Inc.Business Wire • 07/14/20
Verrica Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for VP-102 for the Treatment of Molluscum ContagiosumGlobeNewsWire • 07/14/20
The Law Offices of Frank R. Cruz Continues Its Investigation of Verrica Pharmaceuticals Inc.Business Wire • 07/09/20
Shareholder Alert: Robbins LLP Announces It Is Investigating the Officers and Directors of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of ShareholdersBusiness Wire • 07/06/20
VRCA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the FirmPRNewsWire • 07/02/20
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Verrica Pharmaceuticals Inc.Business Wire • 06/30/20
Verrica Pharmaceuticals Announces Positive Results from Two New Pooled Analyses of the Phase 3 CAMP Trials of VP-102 in Molluscum ContagiosumGlobeNewsWire • 06/12/20
Verrica Pharmaceuticals Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of DirectorsGlobeNewsWire • 06/10/20
Verrica Pharmaceuticals Secures $55 Million in Loan Facilities Led by Silicon Valley BankGlobeNewsWire • 03/11/20
Verrica Pharmaceuticals Announces the Hiring of Two Vice Presidents to Further Grow its Commercial CapabilitiesGlobeNewsWire • 01/29/20
Verrica's NDA Acceptance By FDA For VP-102 May Allow It To Enter Untapped MarketSeeking Alpha • 12/22/19
Verrica Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for VP-102 for the Treatment of Molluscum ContagiosumGlobeNewsWire • 11/27/19
Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology ConferenceGlobeNewsWire • 10/18/19
Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical OperationsGlobeNewsWire • 10/09/19